Aprea Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
Aprea Therapeutics, Inc. filed a Form 8-K dated April 3, 2020, under Item 8.01, Other Events. The filing concerns the scheduling and stockholder-proposal deadlines for the company’s first annual meeting of stockholders.
Financial and Operating Metrics
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, or other financial metrics.
Material Changes Versus Prior Period
The filing does not report a material financial or operating change versus a prior comparable period.
Meeting, Governance Matters, and Outlook
- The 2020 Annual Meeting is expected to be held on Friday, June 26, 2020, at 9:00 a.m. Eastern Time, subject to adjournment or postponement.
- A proxy statement describing the meeting’s business and voting procedures will be distributed before the meeting.
- Rule 14a-8 stockholder proposals must be received by the company’s Secretary at 535 Boylston Street, Boston, Massachusetts 02116, by April 13, 2020, and must comply with applicable SEC requirements.
- Director nominations and other stockholder proposals outside Rule 14a-8 must also be delivered by April 13, 2020, in accordance with the company’s amended and restated bylaws and applicable law.
Key Facts for Investors to Verify
- Confirm whether the annual meeting occurred on June 26, 2020, or was adjourned or postponed.
- Review the subsequent proxy statement for the meeting agenda, voting matters, and board nominees.
- Verify whether any stockholder proposals or director nominations were submitted by the April 13, 2020 deadlines.
- Consult the company’s financial filings for financial metrics and liquidity information, which are not included in this 8-K.